Clinical Trials
9 trialsNCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT06710756 2026-04-30
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT03881488 2026-04-17
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Phase 1 Completed
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed